Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar 13;82(3):555-70.
doi: 10.3797/scipharm.1401-18. Print 2014 Jul-Sep.

HPLC-DAD Method for the Pharmacokinetic Interaction Study of Atorvastatin with Pioglitazone and Cholestyramine in Wistar Rats

Ritesh N Sharma  1 , Shyam S Pancholi  2
Affiliations

HPLC-DAD Method for the Pharmacokinetic Interaction Study of Atorvastatin with Pioglitazone and Cholestyramine in Wistar Rats

Ritesh N Sharma et al. Sci Pharm. .

Abstract

Carotid intima-media thickness is used as a surrogate marker for cardiovascular complications in diabetes mellitus. The combination of atorvastatin and pioglitazone was found to be effective in reducing the thickness of the carotid intima-media layer. The method of RP-HPLC coupled with a diode array detector (DAD) was developed for the pharmacokinetic interaction study of atorvastatin with pioglitazone and cholestyramine, respectively, in Wistar rats. Atorvastatin (ATR) and pioglitazone (PIO) were resolved on a C18 column with a mobile phase composed of 48% methanol, 19% acetonitrile, and 33% 10 mM ammonium formate (v/v/v; pH 3.5±0.3, by formic acid) and a 260 nm detection wavelength on the diode array detector. The method was validated according to international standards with good reproducibility and linear response; mean (r) 0.9987 and 0.9972 to ATR and PIO, respectively. The coefficients of variation of intra- and interassay precision ranged between 4.95-8.12 and 7.29-9.67, respectively. Pharmacokinetic parameters were determined in rats following an oral administration of atorvastatin in the presence and absence of pioglitazone and also with cholestyramine. Compared with the control given atorvastatin alone, the Cmax and AUC of atorvastatin were merely unchanged in rats with the co-administration of pioglitazone, while they decreased by nearly 21 and 15%, respectively, with the concurrent use of cholestyramine. There were no significant changes in Tmax and the plasma half-life (T1/2 ) of atorvastatin in both cases. The performed experiment demonstrated that the presented method was suitable for the estimation and pharmacokinetic interaction study of atorvastatin with pioglitazone and cholestyramine in Wistar rat plasma.

Keywords: Atorvastatin; Cholestyramine; Liquid-liquid Extraction; Pharmacokinetic; Pioglitazone; RP-HPLC-DAD.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Structures of atorvastatin (A), pioglitazone (B), and Valsartan (C, ISTD)
Fig. 2.
Fig. 2.
RP-HPLC chromatograms at 260 nm spiked with ISTD (valsartan) A: LQC; B: in vivo plasma sample obtained after 1.0 h from Wistar rats dosed with atorvastatin and pioglitazone; C: blank rat plasma
Fig. 3.
Fig. 3.
Peak purity curve of A. pioglitazone, B. internal standard, and C. atorvastatin by the diode array detector (DAD)
See this image and copyright information in PMC

References

    1. The National high blood pressure education program working group. Hypertension 1994; 23: 145–148. http://dx.doi.org/10.1161/01.HYP.23.2.145 - DOI - PubMed
    1. Sibal L, Agarwal SC, Home PD. Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes. Diabetes Metab Syndr Obes. 2011; 4: 23–34. http://dx.doi.org/10.2147/DMSO.S8540 - DOI - PMC - PubMed
    1. Yu CM, Zhang Q, Lam L, Lin H, Kong SL, Chan W, Fung JW, Cheng KK, Chan IH, Lee SW, Sanderson JE, Lam CW. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal–medial thickness in patients with coronary heart disease. Heart. 2007; 93: 933–939. http://dx.doi.org/10.1136/hrt.2006.102848 - DOI - PMC - PubMed
    1. Langenfeld MR, Forst T, Hohberg C, Kann P, Lübben G, Konrad T, Füllert SD, Sachara C, Pfützner A. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Circulation. 2005; 111: 2525–2531. http://dx.doi.org/10.1161/01.CIR.0000165072.01672.21 - DOI - PubMed
    1. Forst T, Wilhelm B, Pfützner A, Winfried F, Lehmann U, Schaper F, Weber M, Müller J, Konrad T, Hanefeld M. Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diab Vasc Dis Res. 2008; 5: 298–303. http://dx.doi.org/10.3132/dvdr.2008.043 - DOI - PubMed